| September 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Research and development expenses | $ | 6,006 | $ | 2,516 | ||||
| Payroll and related costs | 2,967 | 4,033 | ||||||
| Other | 1,736 | 1,389 | ||||||
| Total accrued expenses and other current liabilities | $ | 10,709 | $ | 7,938 | ||||
| September 30, 2024 | ||||
| Principal loan balance | $ | 9,500 | ||
| Final fee | 487 | |||
| Unamortized debt discount | (47) | |||
| Total Term Loan | $ | 9,940 | ||
| Less current portion of Term loan | (6,000) | |||
| Term loan | $ | 3,940 | ||
| Shares Available to Grant | Number of Options | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value (in thousands) | ||||||||||||||||
| Balance-December 31, 2023 | 614,041 | 2,364,083 | $ | 8.38 | 7.4 | $ | 2,864 | |||||||||||||
| Change in authorized shares | 5,490,175 | — | — | |||||||||||||||||
| Granted | (3,016,584) | 3,016,584 | 10.23 | |||||||||||||||||
| Exercised | — | (79,987) | 7.62 | |||||||||||||||||
| Forfeited/expired | 51,902 | (51,902) | 7.31 | |||||||||||||||||
| Balance-September 30, 2024 | 3,139,534 | 5,248,778 | $ | 9.47 | 8.4 | $ | 59,491 | |||||||||||||
| Vested and Exercisable-September 30, 2024 | 1,951,828 | $ | 8.08 | 6.7 | $ | 24,833 | ||||||||||||||
| September 30, 2024 | September 30, 2023 | |||||||
| Series A-1 redeemable convertible preferred stock on an as if converted basis | — | 1,065,172 | ||||||
| Series A-2 redeemable convertible preferred stock on an as if converted basis | — | 660,615 | ||||||
| Series A-3 redeemable convertible preferred stock on an as if converted basis | — | 45,673 | ||||||
| Series A-4 redeemable convertible preferred stock on an as if converted basis | — | 6,194 | ||||||
| Series B redeemable convertible preferred stock on an as if converted basis | — | 1,670,599 | ||||||
| Series C redeemable convertible preferred stock on an as if converted basis | — | 3,602,572 | ||||||
| Stock options, issued and outstanding | 5,248,778 | 2,382,765 | ||||||
| Warrants to purchase common stock | 31,690 | 31,690 | ||||||
| Total | 5,280,468 | 9,465,280 | ||||||
| December 31, 2023 | ||||||||||||||||
| (Level 1) | (Level 2) | (Level 3) | Total | |||||||||||||
| Assets: | ||||||||||||||||
| Cash equivalents | $ | 21,061 | $ | — | $ | — | $ | 21,061 | ||||||||
| Liabilities: | ||||||||||||||||
| Convertible promissory notes embedded derivative liability | $ | — | $ | — | $ | 18,183 | $ | 18,183 | ||||||||
| Warrant liability | — | — | 229 | 229 | ||||||||||||
| Total liabilities | $ | — | $ | — | $ | 18,412 | $ | 18,412 | ||||||||
